<DOC>
	<DOCNO>NCT01441570</DOCNO>
	<brief_summary>In open label analysis , nebivolol show positive impact quality life general hypertensive population . That , patient treat nebivolol report less side effect compare treated metoprolol . Also , nebivolol treat patient reach normalization blood pressure . Although data , believe impact would similar renal transplant recipient . The primary goal study determine nebivolol improve quality life measurement kidney transplant recipient compare treated metoprolol succinate . This measure compare score four quality life questionnaires take 12 week treatment study drug . Other aim study determine use nebivolol cost-effective renal transplant recipient ; determine change urine protein excretion renal function use nebivolol ; determine number patient maintain achieve target blood pressure â‰¤ 120/80 mmHg .</brief_summary>
	<brief_title>The Impact Nebivolol Versus Metoprolol Quality Life</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Adult renal transplant recipient , men woman 18 75 year age , inclusive . Patients must &gt; 3 month posttransplant . Patients must stable renal function ( stable renal function define patient without infection hospitalization [ reason ] past 30 day , patient &lt; 20 % change serum creatinine past 30 day . Patients receive corticosteroid must receive daily dose &lt; 7.5 mg prednisone ( therapeutic equivalent base glucocorticoid equivalency scale ) . All eligible patient must receive antihypertensive medication management must include metoprolol tartrate metoprolol succinate . Patients may one medication control hypertension . Use FDAapproved antihypertensive agent permit . All eligible patient either goal blood pressure ( &lt; 120/80 mmHg ) Prehypertension ( &lt; 140/90 mmHg ) Stage I hypertension ( &lt; 160/100 mmHg ) time study inclusion . Patients able comprehend satisfactorily comply protocol requirement . Patients sign write informed consent give prior enter study procedure . Patients Stage II/uncontrolled hypertension ( &gt; 159/99 mmHg ) . Patients easily identifiable etiology fatigue ( i.e . anemia , irondeficiency , poor sleep pattern , etc. ) . Patients medical condition , Investigator 's opinion , would expose increase risk significant adverse event interfere assessment safety efficacy course trial ( i.e . arrhythmia ) . Patients current malignancy , clinically significant hematological , endocrine , cardiovascular , hepatic , gastrointestinal neurological disease ( include form epilepsy ) . If history disease condition stable least past year judge investigator interfere patient 's participation study , patient may include . Patients judge investigator unable unlikely follow study protocol complete schedule visit . Patients contraindication beta blocker therapy list package label metoprolol succinate nebivolol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>kidney</keyword>
	<keyword>transplant</keyword>
	<keyword>hypertension</keyword>
	<keyword>nebivolol</keyword>
	<keyword>metoprolol</keyword>
	<keyword>bystolic</keyword>
	<keyword>toprol</keyword>
</DOC>